JW Pharmaceutical continues governance improvement: Enhanced shareholder communication and 25% dividend payout target, but still lacks CEO succession and risk management policies
2025 consolidated sales KRW 775.3B, operating profit KRW 94.5B, net income KRW 61.5B, up 7.8% and 14.5% YoY respectively, showing improved performance
AGM notice period improved to 4 weeks from 70th AGM (was 2 weeks for 69th), enhancing shareholder access; electronic voting and proxy voting continue
Articles amended to improve dividend predictability (record date after dividend decision) and target 25% consolidated payout ratio for 2026-2028; 2025 dividend KRW 650 per common share (yield 2.1%), 23 consecutive years of dividends
Deficiencies: no formal CEO succession policy, no enterprise risk management policy, exclusion of cumulative voting, no individual evaluation of outside directors, insufficient independence of internal audit support
No history of unfair disclosure; unqualified audit opinions for 3 years; 736,412 treasury shares (no further acquisition)
[AI Summary]This corporate governance report details JW Pharmaceutical's governance practices, showing improvements in shareholder meeting notice timing and dividend predictability. However, deficiencies such as lack of CEO succession and risk management policies indicate limited direct impact on stock price.